MedTrace Logo

Post-market Study on BtHCROSS® for Restoring Facial Volume After a Single Injection

NCT07301619 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2025-12-24

No results posted yet for this study

Summary

This clinical study investigated the safety and effectiveness of BtHCROSS, a hyaluronic acid-based injectable used to restore facial volume and reduce wrinkles. Adults aged 30 to 70 received a single treatment and were monitored over 9 months. Researchers assessed improvements in facial appearance and recorded any side effects. The results aimed to support the product's continued safe use in aesthetic treatments.

Conditions

  • Aesthetics Procedure

Interventions

DEVICE

BtHCROSS®

Single injection of 1 ml of viscoelastic sodium hyaluronate solution crosslinked

Sponsors & Collaborators

  • Dr. Goya Análisis, SL.

    collaborator INDUSTRY

  • i+Med S.Coop.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2023-02-17
Completion
2023-02-17

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07301619 on ClinicalTrials.gov